This was the stock's fifth consecutive day of gains.

Viatris Inc. (VTRS) delivered second-quarter 2025 adjusted earnings of 62 cents per share, which beat the Zacks Consensus Estimate of 56 cents. The company recorded adjusted earnings of 69 cents per ...

Thinking about whether Viatris could be a hidden gem or a value trap? Let’s dig into what the numbers, news, and recent price trends suggest about its real worth. Shares of Viatris have slipped 1.4% ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris ...

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron Sucrose Injection, USP, marking the first generic alternative to Venofer® ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the ...

On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025.

With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about ...

Shares of Viatris Inc. VTRS rose 2.65% to $10.46 Friday, on what proved to be an all-around positive trading session for the ...